Aotearoa Clinical Trials

The trials here

What the 15 trials at this site are about, from their registry records.

Conditions

• Atopic dermatitis (eczema)2 trials
• Chronic kidney disease2 trials
• Psoriasis2 trials
• Psoriatic arthritis2 trials
• Stroke2 trials
• Systemic sclerosis (scleroderma)2 trials
• Acute myeloid leukaemia1 trial
• Coronary artery disease1 trial
• Fatty liver disease (MASLD/MASH)1 trial
• Follicular lymphoma1 trial
• Gout1 trial
• Heart failure1 trial
• and 8 more

Phase

• Phase 38 trials
• Phase 24 trials
• Phase 11 trial
• Phase 1/21 trial

Status

• Recruiting9 trials
• Active, not recruiting3 trials
• Completed3 trials

Lead sponsor

• Eli Lilly and Company3 trials
• Takeda2 trials
• BeiGene1 trial
• BeOne Medicines1 trial
• Boehringer Ingelheim1 trial
• and 7 more

Running trials

• Recruiting

  PRA-216 Atopic Dermatitis Safety and Efficacy Study

  NCT07810777· Phase 2· Prana Therapies Inc· Source

  Contact: Cheng Huang, MD

• Recruiting

  A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

  NCT07497087· Phase 3· Boehringer Ingelheim· Source

  Contact: Boehringer Ingelheim

• Recruiting

  EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

  NCT07287670· Phase 2· Mediar Therapeutics· Source

  Contact: Research Department

• Recruiting

  Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis

  NCT07286058· Phase 3· Takeda· Source

  Contact: Mark Sapsford (principal investigator)

• Recruiting

  A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis

  NCT07235384· Phase 1· Zai Lab (Shanghai) Co., Ltd.· Source

  Contact: ZaiLab Medical Director

• Recruiting

  A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

  NCT07241390· Phase 3· Eli Lilly and Company· Source

  Contact: Kalpa Jayanatha (principal investigator)

• Recruiting

  SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes

  NCT07187531· Phase 2· SAb Biotherapeutics, Inc.· Source

  Contact: Laura Jarrett

• Recruiting

  A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  NCT07165028· Phase 3· Eli Lilly and Company· Source

  Contact: May Shan Lim (principal investigator)

• Active, not recruiting

  A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

  NCT06671483· Phase 3· Takeda· Source

• Active, not recruiting

  The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

  NCT06383390· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

  NCT05020236· Phase 3· Pfizer· Source

• Recruiting

  A Study of BGB-11417 in Participants With Myeloid Malignancies

  NCT04771130· Phase 1/2· BeOne Medicines· Source

  Contact: Study Director

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Atopic dermatitis (eczema)2 recruiting
• Systemic sclerosis (scleroderma)2 recruiting
• Acute myeloid leukaemia1 recruiting
• Chronic kidney disease1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Myelodysplastic syndromes1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting
• Stroke1 recruiting
• Type 1 diabetes1 recruiting

Closed trials

• Completed

  SBD121, a Synbiotic Medical Food for RA Management

  NCT06005220· Solarea Bio, Inc· Source

• Completed

  Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients

  NCT05586971· Phase 3· LG Chem· Source

• Completed

  A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma

  NCT03332017· Phase 2· BeiGene· Source